Ultragenyx Pharmaceutical RARE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $175M+37.8% | $421M+142% | $202.51M+34.5% | $176.31M-63.3% | $127M+13.1% | ||
| $238M-35.2% | $259M-40.6% | $222.74M-52.7% | $311.28M+9.9% | $367.39M+22.5% | ||
| $121M+22.4% | $158M+29.5% | $112.54M+20.6% | $124.46M+17.4% | $98.84M-1.4% | ||
| $55M+19.5% | $52M+15.6% | $52.2M+20.5% | $46.5M+15.8% | $46.03M+28.2% | ||
| $657M-6.0% | $951M+16.4% | $643.21M-19.6% | $719.79M-25.4% | $699.16M+17.3% | ||
| $239M-8.4% | $244M-8.3% | $249.96M-8.3% | $255.76M-8.2% | $260.91M-8.5% | ||
| $44M-0.9% | $44M0.0% | $44.41M0.0% | $44.41M0.0% | $44.41M0.0% | ||
| $174M-1.4% | $176M-1.1% | $172.94M+4.9% | $174.73M+5.1% | $176.52M+7.0% | ||
| $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% | $1.31B+0.4% | ||
| $325M+11.4% | $384M+11.6% | $340.02M+19.3% | $293.24M+7.5% | $291.67M+18.8% | ||
| $1.53B+31.4% | $1.61B+29.3% | $1.17B-0.9% | $1.15B-3.2% | $1.16B-0.5% | ||
| $0-100% | $0— | $96K+4.3% | $96K+4.3% | $94K+13.3% | ||
| -$4.72B-14.8% | -$4.53B-14.5% | -$4.4B-15.2% | -$4.22B-14.4% | -$4.11B-15.4% | ||
| -$236M-264% | -$80M-131% | $9.16M-97.4% | $151.29M-65.0% | $144M+2.7% | ||
| $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% | $1.31B+0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's total assets?
- Ultragenyx Pharmaceutical (RARE) holds $1.3B in total assets, down 1.2% year over year.
- How much cash does Ultragenyx Pharmaceutical have?
- Ultragenyx Pharmaceutical holds $175.0M in cash and equivalents.
- Can Ultragenyx Pharmaceutical cover its short-term obligations?
- Its current ratio is 2.02 — current assets exceed current liabilities.
- Where does Ultragenyx Pharmaceutical's balance sheet data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
